Pharmacokinetic studies of quinobene in dogs (Meeting abstract). NLM AIDSLINE Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Pharmacokinetic studies of quinobene in dogs (Meeting abstract).

Proc Annu Meet Am Assoc Cancer Res; 34:A2369 1993. Unique Identifier : AIDSLINE ICDB/93693321
Mathews L; McCormack J; Bigelow J; Rodman L; Osborn B; Tomaszewski J; Page J; Dept. of Pharmacology, Univ. of Vermont, Burlington, VT 05405

Abstract: Quinobene (QB; NSC 638352) is a synthetic potential anti-HIV drug with a complex structure that includes stilbene, aromatic azo, sulfonate and hydroxyquinoline functionalities. QB was administered iv to beagle dogs at doses ranging from 0.5 to 15 mg/kg and po at 50 and 100 mg/kg. Analysis of QB in plasma samples was accomplished by HPLC (polymeric reversed-phase column; gradient elution with citrate buffer/methanol; detection at 545 nm). 'Peak' plasma concentrations of QB at the higher iv doses were in the 20-40 uM range and elimination of the drug appeared to be biexponential (representative half-lives of 50 and 600 min). While estimates of AUC increase with increasing dose, the AUCs were not directly proportional to dose. Vd and Cl increased with dose as exemplified by estimates of 8 L and 0.01 L/min at 15 mg/kg and 2.5 L and 0.003 L/min at 2.5 mg/kg. QB could not be detected in plasma after oral dosing. Putative metabolites observed in mice were not observed in dogs. No important accumulation of QB in plasma was observed after multiple iv doses.
Keywords: Animal Antiviral Agents/*PHARMACOKINETICS Dogs Dose-Response Relationship, Drug Drug Administration Schedule HIV/DRUG EFFECTS Infusions, Intravenous Metabolic Clearance Rate/PHYSIOLOGY Stilbenes/*PHARMACOKINETICS ABSTRACTKWDanimalantiviralagents/KWDpharmacokineticsdogsdose-responserelationship,drugdrugadministrationschedulehiv/drugeffectsinfusions,intravenousmetabolicclearancerate/physiologystilbenes/KWDpharmacokineticsabstract
931030
M93A0772

Copyright © 1993 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .